Novo Nordisk A/S filings document the Danish healthcare company's financial reporting, product portfolio, pipeline progress and capital structure as a foreign private issuer. Form 6-K reports include operating and financial results, commercial updates for diabetes and obesity medicines, regulatory and clinical disclosures for products such as Wegovy, and development updates in areas including sickle cell disease.
The filing record also covers B-share repurchase programs, treasury-share ownership, share-capital information, governance matters and risk-related disclosures. These reports connect Novo Nordisk's chronic-disease business, GLP-1 franchise, biopharmaceutical research and shareholder-capital actions to formal regulatory disclosure.
Novo Nordisk A/S is repurchasing B shares for up to DKK 11,200,000,010.45 under the programme initiated May 6, 2026, which runs through February 1, 2027. This is part of an overall share repurchase programme of up to DKK 15 billion during the 12-month period beginning February 4, 2026.
By October 16, accumulated repurchases under the May programme were 24,315,000 B shares, with a transaction value of DKK 7,075,024,314. Novo Nordisk reported 53,114,876 B shares held as treasury shares, equal to 1.2% of its share capital. Since February 4, it had repurchased 39,074,179 B shares at an average price of DKK 278.32 per share, with a transaction value of DKK 10,875,024,304.
Novo Nordisk A/S reported 23,090,000 B shares repurchased under the programme launched May 6, with a cumulative transaction value of DKK 6,758,876,433 as of October 9, 2026.
That programme provides for repurchases of up to DKK 11,200,000,010.45 from May 6, 2026 to February 1, 2027, within an overall programme of up to DKK 15 billion during the 12-month period beginning February 4, 2026. As of October 9, 2026, purchases since February 4 totaled 37,849,179 B shares at an average DKK 278.97 per B share, for DKK 10,558,876,422. Novo Nordisk held 51,889,876 B treasury shares, or 1.2% of share capital; total A and B shares, including treasury shares, were 4,465,000,000.
Novo Nordisk A/S is repurchasing B shares for up to DKK 11,200,000,010.45 from May 6, 2026, through February 1, 2027. This programme is part of an overall share repurchase programme of up to DKK 15 billion during the 12-month period beginning February 4, 2026.
After the transactions through October 2, 2026, accumulated repurchases under the May programme were 21,845,000 B shares, with a transaction value of DKK 6,447,270,879. Novo Nordisk held 50,644,876 B shares as treasury shares, equal to 1.1% of its share capital. Separately, since February 4, 2026, the company had repurchased 36,604,179 B shares at an average share price of DKK 279.95 per B share, for a transaction value of DKK 10,247,270,869.
Novo Nordisk A/S (NVO) said the FDA’s review of its denecimig BLA for haemophilia A, with or without inhibitors in adults and children, remains ongoing. The FDA said facility remediation activities are causing the review extension following a pre-license inspection of the manufacturing site and feedback. Novo had anticipated a regulatory decision in the third quarter of 2026, and the FDA has not communicated a new timeline.
The FDA has not identified deficiencies related to denecimig’s clinical efficacy or safety data demonstrated in the FRONTIER programme. Novo said the review extension does not affect its 2026 financial outlook or other marketed products. Pending a regulatory decision, Novo aims to launch denecimig in the US in the first half of 2027. Denecimig has received a positive CHMP opinion and is pending marketing approval from the EMA, while under review by other regulatory authorities.
Novo Nordisk A/S reported additional B-share purchases under a programme allowing repurchases of up to DKK 11,200,000,010.45 from May 6, 2026, through February 1, 2027. The programme is part of an overall share repurchase programme of up to DKK 15 billion over the 12-month period beginning February 4, 2026.
Cumulative purchases under the programme initiated May 6 were 20,620,000 B shares, with a transaction value of DKK 6,139,842,042. Following the reported transactions, Novo Nordisk held 49,419,876 B shares as treasury shares, equal to 1.1% of its share capital. Across the overall programme, purchases since February 4 were reported at DKK 9,939,842,031 as of September 25, 2026, at an average price of DKK 280.95 per B share. The total A and B share count, including treasury shares, was 4,465,000,000.
Novo Nordisk A/S (NVO) reports progress on its ongoing share repurchase programme conducted under EU Safe Harbour rules. The overall programme targets repurchases of up to DKK 15 billion during the 12‑month period beginning February 4, 2026. Under the sub-programme initiated May 6, 2026, the company may repurchase B shares for up to DKK 11,200,000,010.45 through February 1, 2027.
Including the most recent transactions through September 18, 2026, Novo Nordisk has repurchased 34,174,179 B shares at an average price of DKK 281.79, for a total of DKK 9,629,922,935. Novo Nordisk now holds 48,214,876 B shares as treasury shares, equal to 1.1% of its 4,465,000,000 total A and B shares.
Novo Nordisk A/S (NVO) announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending EU marketing authorisation for FREHEMGO® (denecimig) to treat haemophilia A, with or without inhibitors, in adults and children.
FREHEMGO is a next-generation factor VIIIa mimetic bispecific antibody intended for routine prophylaxis to prevent or reduce bleeding episodes, with flexible once-monthly, once-every-two-weeks and weekly dosing in a pre-filled pen. Across the phase 3 FRONTIER programme, denecimig showed consistently low mean annualised bleeding rates, generally below 1, and a substantial proportion of participants experienced zero treated bleeds. A FRONTIER 5 study reported no new safety signals after switching from emicizumab and showed a clear preference for the denecimig device. Denecimig remains under review by the EMA and other regulators, and a Biologics License Application has been submitted to the US FDA.
Novo Nordisk A/S (NVO) reports progress on its ongoing B share repurchase programme conducted under EU Safe Harbour Rules. The programme, which began on May 6, 2026, permits repurchases of B shares for up to DKK 11,200,000,010.45 through February 1, 2027, as part of a broader 12‑month share repurchase plan of up to DKK 15 billion starting February 4, 2026.
Between September 7 and September 11, 2026, the company repurchased 1,050,000 B shares at daily average prices between DKK 278.62 and DKK 297.98, bringing total repurchases under the May programme to 18,325,000 B shares and total repurchases since February 4, 2026 to 33,084,179 B shares at an average price of DKK 281.89, equal to DKK 9,326,186,478. Novo Nordisk now holds 47,124,876 B shares as treasury shares, corresponding to 1.1% of its 4,465,000,000 total A and B shares.
Novo Nordisk A/S (NVO) reports ongoing progress in its B share repurchase activities under its previously announced capital return programme. A specific programme initiated on May 6, 2026 allows repurchases of B shares for up to DKK 11,200,000,010.45 from May 6, 2026 to February 1, 2027, within an overall 12‑month repurchase framework of up to DKK 15 billion beginning February 4, 2026.
Including transactions from August 31 to September 4, 2026, the company has repurchased 17,275,000 B shares under the May 6 programme for a total of DKK 5,221,774,293. As of September 4, 2026, Novo Nordisk has since February 4, 2026 repurchased 32,034,179 B shares at an average price of DKK 281.63, for a total transaction value of DKK 9,021,774,283. Novo Nordisk now holds 46,074,876 B shares as treasury shares, equal to 1.0% of its total share capital of 4,465,000,000 A and B shares.
Novo Nordisk A/S (NVO) reports progress on its ongoing share repurchase programme conducted under EU Safe Harbour Rules. The company plans to repurchase B shares for up to DKK 15 billion during a 12‑month period beginning 4 February 2026, as part of its capital allocation strategy.
Under the sub-programme initiated on 6 May 2026, Novo Nordisk may buy back B shares for up to DKK 11,200,000,010.45 through 1 February 2027. As of 28 August 2026, it has repurchased 30,979,179 B shares at an average price of DKK 281.08, for a total of DKK 8,707,673,805. Novo Nordisk now holds 45,019,876 B shares as treasury shares, equal to 1.0% of its 4,465,000,000 total A and B shares.